Lexaria Bioscience

Lexaria Bioscience FCF per Share

The Free Cash Flow per Share of Lexaria Bioscience (LEXX) as of Nov 19, 2026 is -7.35 USD. In the previous year, Free Cash Flow per Share was -4.50 USD — a change of 63.29% (lower).

FCF per Share

-7.35USD

YoY

63.29%

Last updated:

Free Cash Flow per Share of Lexaria Bioscience is 2025 -7.35 USD. Free Cash Flow per Share of Lexaria Bioscience was 2024 -4.50 USD. It decreases by 63.29% lower compared to the previous year.

The Lexaria Bioscience FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-15.37 USD
Jan 1, 2019
-21.47 USD
Jan 1, 2020
-13.26 USD
Jan 1, 2021
-10.66 USD
Jan 1, 2022
-12.42 USD
Jan 1, 2023
-10.03 USD
Jan 1, 2024
-4.50 USD
Jan 1, 2025
-7.35 USD
The Lexaria Bioscience FCF per Share history
YEARFCF per ShareYoY
-7.35USD+63.29%
-4.50USD-55.11%
-10.03USD-19.28%
-12.42USD+16.57%
-10.66USD-19.60%
-13.26USD-38.27%
-21.47USD+39.71%
-15.37USD+50.66%
-10.20USD+72.12%
-5.93USD-62.43%
-15.77USD-492.67%
4.02USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lexaria Bioscience Stock analysis

What does Lexaria Bioscience do? Lexaria Bioscience Corp. generates revenue through its DehydraTECH drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients. The company operates in two segments: Intellectual Property and Products, licensing its patented technology to partners in the pharmaceutical industry. DehydraTECH formulations improve oral absorption and have demonstrated enhanced delivery into brain tissue, supporting applications for intraoral and topical administration. The firm holds 35 granted patents and numerous pending patents worldwide, leveraging its intellectual property portfolio for licensing agreements. The company's primary customers are pharmaceutical firms seeking to improve drug delivery for oral, intraoral, and topical formulations. These partners utilize DehydraTECH to increase the effectiveness of active molecules, particularly for applications requiring higher bioavailability or targeted brain delivery. Lexaria's technology is positioned to support the development of new pharmaceutical products without direct manufacturing involvement. Lexaria's business model relies on licensing its patented DehydraTECH technology to pharmaceutical companies, generating income through intellectual property agreements. The company does not produce or sell finished pharmaceutical products but instead focuses on technology licensing and intellectual property management. Its subsidiary Lexa is part of the corporate structure but does not drive revenue generation. Lexaria Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lexaria Bioscience stock

Free Cash Flow per Share of Lexaria Bioscience is -7.35 USD in 2025.

Free Cash Flow per Share of Lexaria Bioscience changed from -4.50 USD to -7.35 USD, representing a 63.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Lexaria Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Lexaria Bioscience

All Key Metrics — Lexaria Bioscience